Feature | May 16, 2013

Multiple Studies Show Promise for Innovative FIRM Rotor Mapping Method

New mapping method could greatly improve and shorten AFib ablation procedures, but debate persists over question of rotor mobility

May 16, 2013 — New research presented at Heart Rhythm 2013 continues to show promising results for focal impulse and rotor modulation (FIRM) mapping to effectively target atrial fibrillation (AF) sources and improves ablation therapy outcomes. The novel diagnostic real-time mapping system helps target ablation therapy to patient-specific drivers of AF rather than to anatomical targets, which can improve patient outcomes.

More than 2 million people in the United States have AF, a common heart rhythm disorder which causes an irregular and rapid heartbeat. Although it is not life threatening, AF can lead to other problems including chronic fatigue, congestive heart failure and stroke.

“This new procedure has the potential to dramatically change how we treat patients with atrial fibrillation,” said Vijay Swarup, M.D., FHRS, director of cardiac electrophysiology at Arizona Heart Hospital. “New findings help us better understand that small electrical spinning tops – rotors – or focal sources drive AF, the stability of these sources and exactly where to treat them.”

New research builds on the CONFIRM trial findings from 2011 that first showed AF was acutely terminated or substantially slowed with less than 10 minutes of FIRM-guided ablation per identified source.

A new study, led by Robert Kowal, M.D., and presented at Heart Rhythm 2013, provides more information on how FIRM-guided ablation effectively treats AF. FIRM mapping was performed in 210 patients at 11 U.S. centers. Ablation was targeted prospectively at rotors or focal sources in 132 consecutive patients, of whom 25 percent had paroxysmal AF and 75 percent had persistent AF. FIRM-guided ablation achieved an acute endpoint in 82.9 percent of patients with ten minutes of total ablation. This included terminating AF and rendering it noninducible in 55.8 percent of patients, in whom the majority (69 percent) terminated to sinus rhythm and 31 percent terminated to atrial tachycardia.

A second study, led by Swarup, used FIRM to map where electrical rotors or focal sources are located in the heart and found that sources exist in diverse stable locations throughout the atria. The 11-multicenter prospective trial mapped AF in 210 consecutive patients, of whom 132 had FIRM-guided ablation at rotor or focal sources of AF. Sources were revealed in 99.2 percent of patients, and more than half of the AF sources were located away from pulmonary veins. These results further confirm the importance of mapping AF sources in each patient compared to traditional pulmonary vein isolation therapy. In FIRM guided patients, AF termination or 10 percent slowing was achieved.

FIRM rotor mapping has spurred some debate in EP because it is believed by some that these rotors move. If they are stationary, the ablations can be very successful, but if they move, as some believe, relief from AF might only be temporary following a FIRM procedure. 

For more information: www.HRSonline.org

Related Content

Trial Data Shows Positive Predictive Results for Boston Scientific HeartLogic Heart Failure Diagnostic
News | Heart Failure| October 20, 2017
October 20, 2017 — Boston Scientific announced new data from the Multisensor Chronic Evaluation in Ambulatory Heart F
Smartphone Apps Help Patients and Providers Manage Atrial Fibrillation
News | Patient Engagement| October 19, 2017
October 19, 2017 — Novel smartphone and tablet applications for atrial fibrillation patients and healthcare professio
The Respicardia Remede System is a pacemaker-like device designed to improve cardiovascular health by restoring natural breathing during sleep in patients with Central sleep apnea.
Technology | Heart Failure| October 18, 2017
October 18, 2017 — The U.S.
Baylis Medical and Siemens Co-Sponsor Transseptal Access Training Course
News | EP Lab| October 18, 2017
Baylis Medical Co. Inc. and Siemens Healthineers are co-sponsoring a first-of-its kind training program aimed at...
CardioFocus Announces European CE Mark Approval of HeartLight Excalibur Balloon
Technology | Ablation Systems| October 10, 2017
October 10, 2017 — CardioFocus Inc. recently announced the European CE Mark approval of the HeartLight Excalibur Ball
The Apama Radiofrequency (RF) Balloon Catheter System.
News | Ablation Systems| October 02, 2017
October 2, 2017 — Boston Scientific announced a definitive agreement to acquire Apama Medical Inc., a privately-held
Boston Scientific Launches Resonate Devices With HeartLogic Heart Failure Diagnostic
Technology | Implantable Cardioverter Defibrillator (ICD)| September 27, 2017
September 27, 2017 — Boston Scientific recently launched the Resonate family of...
Spectranetics Initiates Class I Recall for Bridge Occlusion Balloon Catheter
News | EP Lab| September 27, 2017
Spectranetics is recalling its Bridge Occlusion Balloon Catheter due to the possibility of a blocked guidewire lumen in...
Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD
Technology | Implantable Cardioverter Defibrillator (ICD)| September 22, 2017
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Overlay Init